02 8011 4217, 0416 974 651  info at scenar.com.au

Analgesia With Device For Sensory Restoration

Abstracts of the 18th MASCC International Symposium

Support Care Cancer (2006) 14: 583–687 DOI 10.1007/s00520-006-0078-x

Analgesia With Device For Sensory Restoration.

Boris Zaidiner1, Ilya Baranovsky2, Alexei Dmitrenko31 City Cancer Hospital, 2Medical unit “Zdorov’e”, 3City Cancer Hospital

Background: Cancer pain relief has still some problems. In the attempt to contribute solving them, we have presented data on the usage of the new device which was designed for sensory system restoration with transcutaneous electrical stimulation; its analgesic activity was accidentally noted in some patients (pts).

Methods: Our preliminary trial was conducted in 34 pts (men 16, women 18; mean age 55.3) who had various nosologic forms of malignancies with chronic pain syndromes. As was verified, the origin of pain was caused by generalized cancer process (tumor growth and/or remote metastases) in all cases. The pts were administrated analgesic drugs with WHO recommendations but they continued to suffer from pain. After signing the informed consent these pts received additional therapeutic course which consisted of 10…15 procedures.

For the resuIts of this treatment to assess pain intensity (PI) and pain relief (PR) were recorded. PI was evaluated with categorical rating scale (CRS), its range varied from 0 (“no pain”) up to 10 (“pain as bad as I can imagine”). PR was rated
using 5-point scale; its range was from 0 (“none”) to 4 (“complete”).

Results: The average baseline CRS score was 6.1. In 23 pts of 34 (67,6%) good results were achieved: CRS < 3 and PR 3…4 with reduction of drug usage. 8 pts (23.5) had moderate results: CRS 3…5, PR 2; in 3 pts the results were bad (CRS > 5, PR 0…1). Besides pain relief depressive symptoms were regressed in 17 of 26 pts who had such disorders; this antidepressive action was confirmed with both clinical observation and data on routine HAM-D scale (?50% declining).

Conclusion: The new device is useful in cancer pain relief as a part of comprehensive therapeutic program. Its exact position here will be established in the randomized placebo-controlled study that is being conducted now.